Cargando…

A Rare Case of p190 BCR-ABL B-cell Acute Lymphocytic Leukemia With Excellent Response to Hyper-CVAD and Ponatinib

Acute lymphoblastic leukemia (ALL) is a hematologic cancer that begins in the bone marrow and results in an overproduction of lymphocytes. It can present as palpable purpura, which is also seen in many other pathologies, including vasculitides such as IgA vasculitis. We present a case of a 52-year-o...

Descripción completa

Detalles Bibliográficos
Autores principales:	DeRon, Nathan, Jivraj, Sereena, McCreight, Hannah, Permann, Austin, Oluwadamilola, Babaniji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9872561/ https://www.ncbi.nlm.nih.gov/pubmed/36699758 http://dx.doi.org/10.7759/cureus.32921

Ejemplares similares

Ponatinib Is a Pan-BCR-ABL Kinase Inhibitor: MD Simulations and SIE Study
por: Tanneeru, Karunakar, et al.
Publicado: (2013)

The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model
por: Pouwer, Marianne G., et al.
Publicado: (2018)

Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia
por: Kaur, Pavinder, et al.
Publicado: (2007)

Beyond Hyper-CVAD in ALL: Highlights From SOHO 2021
Publicado: (2022)

Combining the ABL1 Kinase Inhibitor Ponatinib and the Histone Deacetylase Inhibitor Vorinostat: A Potential Treatment for BCR-ABL-Positive Leukemia
por: Okabe, Seiichi, et al.
Publicado: (2014)

Excellent survival after R‐Hyper‐CVAD in hospitalized patients with high‐risk large B‐cell lymphoma: The Karolinska experience
por: Sonnevi, Kristina, et al.
Publicado: (2021)

Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment
por: Oaxaca, Derrick M., et al.
Publicado: (2016)

Modelling ponatinib resistance in tyrosine kinase inhibitor-naïve and dasatinib resistant BCR-ABL1+ cell lines
por: Lu, Liu, et al.
Publicado: (2018)

Emergence of BCR-ABL1 (p190) in Acute Myeloid Leukemia Post-Gilteritinib Therapy
por: Kim, Heejeong, et al.
Publicado: (2023)

The targetable role of herpes virus-associated ubiquitin-specific protease (HAUSP) in p190 BCR-ABL leukemia
por: Carrà, Giovanna, et al.
Publicado: (2016)

KLF5 controls glutathione metabolism to suppress p190-BCR-ABL+ B-cell lymphoblastic leukemia
por: Zhang, Cuiping, et al.
Publicado: (2018)

Chronic Myeloid Leukemia With P190 BCR-ABL Translocation and Persistent Moderate Monocytosis: A Case Report
por: Gatti, Arianna, et al.
Publicado: (2018)

Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets
por: Adnan-Awad, Shady, et al.
Publicado: (2020)

Hyper-CVAD-Based Stem Cell Microtransplant as Post-Remission Therapy in Acute Lymphoblastic Leukemia
por: Cai, Bo, et al.
Publicado: (2022)

c-Myb and its target Bmi1 are required for p190BCR/ABL leukemogenesis in mouse and human cells
por: Waldron, Todd, et al.
Publicado: (2011)

Coexistence of P190 and P210 BCR/ABL transcripts in chronic myeloid leukemia blast crisis resistant to imatinib
por: Junmei, Zhao, et al.
Publicado: (2015)

Frequency of p190 and p210 BCR-ABL rearrangements and survival in Brazilian adult patients with acute lymphoblastic leukemia
por: de França Azevedo, Ilana, et al.
Publicado: (2014)

Differential signaling networks of Bcr–Abl p210 and p190 kinases in leukemia cells defined by functional proteomics
por: Reckel, S, et al.
Publicado: (2017)

Long-Term Survival after T-cell Lymphoblastic Lymphoma Treated with One Cycle of Hyper-CVAD Regimen
por: Ryu, Il Hwan, et al.
Publicado: (2015)

Complete remission with romidepsin in a patient with T‐cell acute lymphoblastic leukemia refractory to induction hyper‐CVAD
por: Brunvand, Mark W., et al.
Publicado: (2017)

Retinal and Preretinal Hemorrhages in a Patient Receiving Hyper-CVAD Chemotherapy for T-Cell Acute Lymphoblastic Leukemia
por: Peddada, Krishi, et al.
Publicado: (2018)

RAS and TP53 can predict survival in adults with T‐cell lymphoblastic leukemia treated with hyper‐CVAD
por: Sakhdari, Ali, et al.
Publicado: (2019)

Adult acute megakaryoblastic leukemia: rare association with cytopenias of undetermined significance and p210 and p190 BCR–ABL transcripts
por: Dima, Delia, et al.
Publicado: (2017)

Effectiveness of modified hyper‐CVAD chemotherapy regimen in the treatment of adult acute lymphoblastic leukemia: a retrospective experience
por: Jalaeikhoo, Hasan, et al.
Publicado: (2018)

Cytarabine Induced Acute Cerebellar Syndrome during Hyper-CVAD Treatment for B-Cell Acute Lymphoblastic Leukemia
por: Tran, Phu Ngoc, et al.
Publicado: (2017)

Optimal Molecular Methods in Detecting p190(BCR-ABL) Fusion Variants in Hematologic Malignancies: A Case Report and Review of the Literature
por: Sonu, Rebecca J., et al.
Publicado: (2015)

P190(BCR-ABL) Chronic Myeloid Leukemia Following a Course of S-1 Plus Oxaliplatin Therapy for Advanced Gastric Adenocarcinoma
por: Wang, Hua, et al.
Publicado: (2017)

A Rare Case of p190 BCR-ABL Chronic Myeloid Leukemia With a Very Good Response to Tyrosine Kinase Inhibitors
por: Gandhe, Nalinikumari, et al.
Publicado: (2021)

A case of e1a2 (minor, P190) BCR-ABL1-positive chronic myeloid leukemia in Korea
por: Choi, Yu Jeong, et al.
Publicado: (2021)

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
por: Mian, Afsar Ali, et al.
Publicado: (2012)

The Use of R-Hyper-CVAD in a Rare Case of Primary Bone Marrow Diffuse Large B-Cell Lymphoma
por: Reed, Allison, et al.
Publicado: (2019)

Prognostic Factors and Outcome of Patients with Adult Acute Lymphoblastic Leukemia Treated with the Hyper-CVAD Regimen: A Retrospective Study
por: Malakoutikhah, Zahra, et al.
Publicado: (2023)

Coexistence of p190 BCR/ABL Transcript and CALR 52-bp Deletion in Chronic Myeloid Leukemia Blast Crisis: A Case Report
por: Seghatoleslami, Mohammad, et al.
Publicado: (2016)

Targeting BCR-ABL(+) stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex
por: Chen, Min, et al.
Publicado: (2017)

An Unprecedented Case of p190 BCR-ABL Chronic Myeloid Leukemia Diagnosed during Treatment for Multiple Myeloma: A Case Report and Review of the Literature
por: Miki, Kosuke, et al.
Publicado: (2018)

Jak2/STAT6/c-Myc pathway is vital to the pathogenicity of Philadelphia-positive acute lymphoblastic leukemia caused by P190(BCR-ABL)
por: Qin, Run, et al.
Publicado: (2023)

BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
por: Sharma, Nitesh, et al.
Publicado: (2015)

Pterostilbene downregulates BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells
por: Kawakami, Shohei, et al.
Publicado: (2022)

Oncogenic Stress Induced by Acute Hyper-Activation of Bcr-Abl Leads to Cell Death upon Induction of Excessive Aerobic Glycolysis
por: Dengler, Michael A., et al.
Publicado: (2011)

P190(BCR-ABL1) in a Patient with Philadelphia Chromosome Positive T-Cell Acute Lymphoblastic Leukemia: A Rare Case Report and Review of Literature
por: Kohla, Samah, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_30mk6dftr6onfc09695avjalp3